Medical Editor: John P. Cunha, DO, FACOEP
Humalog Mix 75/25 [75% insulin lispro protamine suspension and 25% insulin lispro injection, (rDNA origin)] injection is a combination of two man-made insulins used to treat type 1 (insulin-dependent) or type 2 (non-insulin-dependent) diabetes. The combination of insulins in Humalog Mix 75/25 starts working faster and lasts for a longer time than regular insulin. Common side effects of Humalog Mix 75/25 include:
- low blood sugar (hypoglycemia)
- swelling of hands and feet
- injection site reactions (pain, redness, swelling, or itching)
A side effect of too much insulin is low blood sugar (hypoglycemia), which includes symptoms such as:
- cold sweats
- blurred vision
- fast heartbeat
- tingling of the hands/feet
If any of these symptoms occur, tell your doctor immediately.
Dosage regimens of Humalog Mix 75/25 vary and are determined by the doctor familiar with the patient's metabolic needs, eating habits, and other lifestyle variables. Humalog Mix75/25 is intended only for subcutaneous administration. Humalog Mix75/25 may interact with medications with hyperglycemic activity such as corticosteroids, isoniazid, certain lipid-lowering drugs (e.g., niacin), estrogens, oral contraceptives, phenothiazines, and thyroid replacement therapy. Discuss with your doctor all medications and supplements you use. Tell your doctor if you are pregnant before using Humalog Mix 50/50. Discuss a plan for managing blood sugars with your doctor before becoming pregnant. Your doctor may switch the type of insulin you use during pregnancy. It is unknown if this drug passes into breast milk. Insulin needs may change while breastfeeding. Consult your doctor before breastfeeding.
Our Humalog Mix75/25 [75% insulin lispro protamine suspension and 25% insulin lispro injection, (rDNA origin)] Injection Side Effects Drug Center provides a comprehensive view of available drug information on the potential side effects when taking this medication.
This is not a complete list of side effects and others may occur. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.
Pain, redness, swelling or itching at the injection site may occur. These effects usually go away after a few days or weeks. If any of these effects persist or worsen, notify your doctor or pharmacist promptly.
Remember that your doctor has prescribed this medication because he or she has judged that the benefit to you is greater than the risk of side effects. Many people using this medication do not have serious side effects.
Too much insulin can cause low blood sugar (hypoglycemia). This effect may also occur if you do not consume enough calories. The symptoms include chills, cold sweats, blurred vision, dizziness, drowsiness, shaking, fast heartbeat, weakness, headache, fainting, tingling of the hands/feet, or hunger. It is a good habit to carry glucose (sugar) tablets or gel to treat low blood sugar. If you don't have these reliable forms of glucose, raise your blood sugar quickly by eating a quick source of sugar such as table sugar, honey, candy, or drinking a glass of fruit juice or non-diet soda. Tell your doctor immediately about the reaction. To help prevent low blood sugar, eat meals on a regular schedule and do not skip meals.
Too little insulin can cause high blood sugar (hyperglycemia). Symptoms of high blood sugar include thirst, increased urination, confusion, drowsiness, flushing, rapid breathing, or fruity breath odor. If these symptoms occur, tell your doctor immediately. Your treatment plan may need to be changed.
This medication may cause low potassium levels in the blood (hypokalemia). Tell your doctor immediately if any of these unlikely but serious side effects occur: muscle cramps, weakness, irregular heartbeat.
A very serious allergic reaction to this drug is rare. However, seek immediate medical attention if you notice any of the following signs of a serious allergic reaction: rash, itching/swelling (especially of the face/tongue/throat), severe dizziness, trouble breathing.
This is not a complete list of possible side effects. If you notice other effects not listed above, contact your doctor or pharmacist.
In the US -
Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.
In Canada - Call your doctor for medical advice about side effects. You may report side effects to Health Canada at 1-866-234-2345.
Read the entire patient information overview for Humalog 75-25 (75-25 Insulin Lispro Suspension and 25 Insulin Lispro Injection)
The following adverse reactions are discussed elsewhere in the labeling:
- Hypoglycemia [see WARNINGS AND PRECAUTIONS]
- Medication Errors [see WARNINGS AND PRECAUTIONS]
- Hypersensitivity Reactions [see WARNINGS AND PRECAUTIONS]
- Hypokalemia [see WARNINGS AND PRECAUTIONS]
Adverse Reactions From Clinical Studies Or Postmarketing Reports
The following adverse reactions have been identified during post-marketing use of HUMALOG Mix75/25. Because some of these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.
Adverse Reactions Associated With Insulin Initiation And Glucose Control Intensification
Intensification or rapid improvement in glucose control has been associated with a transitory, reversible ophthalmologic refraction disorder, worsening of diabetic retinopathy, and acute painful peripheral neuropathy. Over the long-term, improved glycemic control decreases the risk of diabetic retinopathy and neuropathy.
Severe, life-threatening, generalized allergy, including anaphylaxis.
Hypoglycemia is the most commonly observed adverse reaction in HUMALOG Mix75/25.
HUMALOG Mix75/25 can cause a shift in potassium from the extracellular to intracellular space, possibly leading to hypokalemia.
Injection Site Reactions
HUMALOG Mix75/25 can cause local injection site reactions including redness, swelling, or itching at the site of injection. These reactions usually resolve in a few days to a few weeks, but in some occasions, may require discontinuation. Localized reactions and generalized myalgias have been reported with the use of meta-cresol, which is an excipient in HUMALOG Mix75/25.
Administration of insulin subcutaneously, including HUMALOG Mix75/25, has resulted in lipoatrophy (depression in the skin) or lipohypertrophy (enlargement or thickening of tissue) [see DOSAGE AND ADMINISTRATION] in some patients.
Medication errors in which other insulins have been accidentally substituted for HUMALOG Mix75/25 have been identified during postapproval use.
Insulin, including HUMALOG Mix75/25, may cause sodium retention and edema, particularly if previously poor metabolic control is improved by intensified insulin therapy.
Weight gain can occur with insulin therapy, including HUMALOG Mix75/25, and has been attributed to the anabolic effects of insulin and the decrease in glycosuria.
As with all therapeutic peptides, insulin administration may cause anti-insulin antibodies to form. The incidence of antibody formation with HUMALOG Mix75/25 is unknown.
Read the entire FDA prescribing information for Humalog 75-25 (75-25 Insulin Lispro Suspension and 25 Insulin Lispro Injection)
© Humalog 75-25 Patient Information is supplied by Cerner Multum, Inc. and Humalog 75-25 Consumer information is supplied by First Databank, Inc., used under license and subject to their respective copyrights.